Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Income (2016 - 2025)

Historic Net Income for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $15.9 million.

  • Ptc Therapeutics' Net Income rose 11490.43% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.4 million, marking a year-over-year increase of 19032.47%. This contributed to the annual value of -$625.6 million for FY2024, which is 1253.16% up from last year.
  • Ptc Therapeutics' Net Income amounted to $15.9 million in Q3 2025, which was up 11490.43% from -$64.8 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Net Income high stood at $866.6 million for Q1 2025, and its period low was -$328.2 million during Q4 2024.
  • For the 5-year period, Ptc Therapeutics' Net Income averaged around -$84.7 million, with its median value being -$128.6 million (2021).
  • In the last 5 years, Ptc Therapeutics' Net Income tumbled by 9173.51% in 2021 and then soared by 104627.63% in 2025.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Net Income stood at -$143.3 million in 2021, then fell by 21.82% to -$174.5 million in 2022, then crashed by 40.05% to -$244.4 million in 2023, then tumbled by 34.27% to -$328.2 million in 2024, then soared by 104.84% to $15.9 million in 2025.
  • Its Net Income stands at $15.9 million for Q3 2025, versus -$64.8 million for Q2 2025 and $866.6 million for Q1 2025.